FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/02/2024
Back to search
Official data from USPTO
ODYSSION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ODYSSION
ST13
US500000079352298Class
1, 5, 42
Filing
79352298
Registration
7296103
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
06/02/2024
Trademark type
Word
Nice classes
1, 5, 42
Filing date
05/24/2022
Registration date
02/06/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/06/2024
Last transaction
02/06/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
ALLEN, BIANCA LEIGH
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
OMASS Therapeutics Limited
Representatives
Rebecca Liebowitz Venable LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Reagents for use in medical research and scientific research being biological analysis; proteins for use in the manufacture of pharmaceuticals and reagents; proteins in raw material form for use in medical research; cellscell linescell culturesall being cells for clinical laboratory usefor use in the production of proteins for therapeutic use
Class 5
Pharmaceutical and veterinary preparations and substances for the treatment of immune response disordersgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseasesinfectious diseases and cardiovascular diseases; biopharmaceutical preparations and substances for treatment of immune response disordersgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseasesinfectious diseases and cardiovascular diseases; chemicalbiochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disordersgenetic conditionscancerophthalmological conditionshematologic diseasesneurological disordersrespiratory diseasesmetabolic diseasesinfectious diseases and cardiovascular diseases; cellscell linescell culturesall being cells for medical usefor use in the production of proteins for therapeutic use; reagents for medical useproteins being medical therapeutic reagents; therapeutic antibodies; vaccines
Class 42
Scientific and technological servicesscientific research and design relating thereto in the field of analytical sciencesbiophysicschemistrybiochemistrybiotechnologymolecular sciences and mass spectrometry; laboratory research services in the field of analytical sciencesbiophysicschemistrybiochemistrybiotechnologymolecular sciences and mass spectrometry; medical and pharmacological research services; scientific researchscientific analysis and testing being measurement of substances in the field of analytical sciencesbiophysicschemistrybiochemistrybiotechnologymolecular sciences and mass spectrometry; scientific analysis and measurement of molecules and characteristics in the field of analytical sciencesbiophysicschemistrybiochemistrybiotechnologymolecular sciences and mass spectrometry; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research and medical development services in the field of immunologygenetic conditionsoncologyimmuno-oncologyophthalmologyhaematologyneurologyrespiratory diseasesmetabolic conditionsinfectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnological researchbiotechnology scientific testingin the biotechnicalbiomedical and pharmaceutical fields; chemical research and analysis; research and development of new products for others in the biotechnicalbiomedical and pharmaceutical fields; pharmaceutical research and development for the pharmaceutical industry; research and development of vaccines and medicines; scientific research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; scientific research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical researchdevelopment and testing being product testing services; drug discovery services; product developmentdrug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; scientific research and development of molecules for therapeutic purposes; consultancyadvisory and information services in relation to all the aforesaid services
Publications
History of USPTO decisions and trademark events.
31 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/10/2024
FIMP
FINAL DISPOSITION PROCESSED
05/10/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/06/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/06/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
02/06/2024
GPNX
NOTIFICATION PROCESSED BY IB
11/21/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/21/2023
PUBO
PUBLISHED FOR OPPOSITION
11/21/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/01/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/16/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
10/16/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/16/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
10/16/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/16/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/07/2023
DOCK
ASSIGNED TO EXAMINER
09/18/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/20/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/19/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/19/2023
RFNT
REFUSAL PROCESSED BY IB
05/24/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/04/2023
RFRR
REFUSAL PROCESSED BY MPU
05/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/16/2023
CNRT
NON-FINAL ACTION WRITTEN
03/15/2023
DOCK
ASSIGNED TO EXAMINER
03/13/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/14/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/13/2022
Continuous trademark protection
Get notified about every new filing that threatens ODYSSION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.